61667-16-1

Basic information

• Product Name: N-Benzyl-6-chloro-4-pyrimidinamine
• Synonyms: N-Benzyl-6-chloro-4-pyrimidinamine;4-BenzylaMino-6-chloropyriMidine, 96%;N-Benzyl-6-chloropyrimidin-4-amine
• CAS NO: 61667-16-1
• Molecular Formula: C₁₁H₁₀ClN₃
• Molecular Weight: 219.6702
• Mol File: 61667-16-1.mol
• Article Data: 10

Chemical Properties

• Melting Point: 116-117℃
• Boiling Point: 381 °C at 760 mmHg
• Flash Point: 184.2 °C
• Appearance: /
• Density: 1.307 g/cm³
• CAS DataBase Reference: N-Benzyl-6-chloro-4-pyrimidinamine(CAS DataBase Reference)
• NIST Chemistry Reference: N-Benzyl-6-chloro-4-pyrimidinamine(61667-16-1)
• EPA Substance Registry System: N-Benzyl-6-chloro-4-pyrimidinamine(61667-16-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 61667-16-1(Hazardous Substances Data)

Usage

General Description

N-Benzyl-6-chloro-4-pyrimidinamine is a chemical compound with the molecular formula C12H10ClN3. It is an organic compound that consists of a benzene ring attached to a pyrimidine ring with a chloro group at the 6th position. N-Benzyl-6-chloro-4-pyrimidinamine is commonly used in the pharmaceutical industry as an intermediate in the synthesis of various pharmaceutical drugs. It has applications in the production of anti-cancer and anti-inflammatory drugs, as well as in the study of bioactive molecules. N-Benzyl-6-chloro-4-pyrimidinamine is a valuable compound in the field of medicinal chemistry due to its potential for drug development and therapeutic applications.

Upstream product

• 1193-21-1 4,6-dichloropyrimidine 
• 100-46-9 benzylamine 

Downstream Products

• 1360179-77-6 N-benzyl-(6-morpholino-4-pyrimidinyl)-acetamide 
• 1360179-76-5 N-benzyl-6-morpholino-N-nitrosopyrimidin-4-amine 

Relevant articles and documents

1,4,9-Triazaspiro[5.5]undecan-2-one Derivatives as Potent and Selective METTL3 Inhibitors

N6-methyladenosine (m6A) is the most frequent of the 160 RNA modifications reported so far. Accumulating evidence suggests that the METTL3/METTL14 protein complex, part of the m6A regulation machinery, is a key player in a variety of diseases including several types of cancer, type 2 diabetes, and viral infections. Here we report on a protein crystallography-based medicinal chemistry optimization of a METTL3 hit compound that has resulted in a 1400-fold potency improvement (IC50 of 5 nM for the lead compound 22 (UZH2) in a time-resolved F?rster resonance energy transfer (TR-FRET) assay). The series has favorable ADME properties as physicochemical characteristics were taken into account during hit optimization. UZH2 shows target engagement in cells and is able to reduce the m6A/A level of polyadenylated RNA in MOLM-13 (acute myeloid leukemia) and PC-3 (prostate cancer) cell lines.

PYRIMIDINE FGFR4 INHIBITORS

Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.

Effect of substituent structure on pyrimidine electrophilic substitution: A rebuttal

The report about a series of unexpected and obscure effects influencing the electrophilic nitrosation of activated pyrimidines (Tetrahedron 2007, 63, 5394) was shown to be erroneous. Instead of electrophilic substitution at position 5 of the pyrimidine ring, N-nitrosation of the secondary amino group in the 4-position of the pyrimidine ring took place. Moreover it was shown that the synthetic sequence for the preparation of purines is also incorrect.